The cancer-associated mutations evaluated in this study destabilize MEP50, likely impacting methylosome complex integrity and PRMT5 enzymatic activity, thereby disrupting hormone signaling and DNA repair pathways. The gene discussed is PRMT5; the disease is cancer.